Revagenix Inc Federal Contracts
Revagenix Inc of San Mateo, California won $14.2 million in federal contracts from Oct 18, 2025 to Oct 18, 2026, mostly from the National Institutes of Health, for research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology).
| Unique Entity ID (UEI) | D98QFZUPFXJ9 |
|---|---|
| Location | San Mateo, California |
| Parent company | Revagenix Inc |
| Business types | Small business |
Agencies that paid Revagenix Inc
- National Institutes of Health: $14.2 million
What Revagenix Inc sells to the government
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (NAICS 541715): $14.2 million
Revagenix Inc's largest contracts with recent activity
- $28.2 million, National Institutes of Health, from Sep 22, 2022: A novel lpxc inhibitor with pan-resistant pseudomonas and burkholderia activity. (75N93022C00061)
- $26.9 million, National Institutes of Health, from Jul 1, 2020: To select a novel small molecule antibiotic for clinical development and advance it through ind filing and phase 1 clinical studies. (75N93020C00018)
Amounts are each contract's total value; the contracts had spending in the last 12 months.
Open bids in Revagenix Inc's trades
253 open federal notices today are in the trades Revagenix Inc sells most. The newest:
Award figures: contract obligations reported to USAspending.gov, read Oct 18, 2026.
Questions about Revagenix Inc
How much does Revagenix Inc get in federal contracts?
$14.2 million in contract obligations from Oct 18, 2025 to Oct 18, 2026, the most from the National Institutes of Health ($14.2 million).
What does Revagenix Inc sell to the federal government?
research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology).